NCT00489840View on ClinicalTrials.gov

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2010

Conditions
Chronic Central Serous Chorioretinopathy
Interventions
DRUG

Anecortave Acetate Sterile suspension 15 mg

anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months

DRUG

Anecortave Acetate

anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.

Trial Locations (2)

10021

Manhattan Eye, ear & Throat Institute, New York

10022

Vitreous-Retina-Macula Consultants of New York,PC, New York

Sponsors

Collaborators (1)

Alcon Research
All Listed Sponsors
collaborator

LuEsther T. Mertz Retinal Research Center

OTHER

collaborator

Alcon Research

INDUSTRY

lead

Manhattan Eye, Ear & Throat Hospital

OTHER

NCT00489840 - Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate | Biotech Hunter | Biotech Hunter